开云app官网登录入口网页版-官方正版

#不耐受#

29篇内容 | 1324人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1947230, encodeId=81e3194e230ce, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=常用抗血小板药物不耐受、反应性低？这些治疗策略要掌握！, objectType=article, longId=737170, objectId=d02de371705d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d02de371705d, replyNumber=0, likeNumber=59, createdTime=2022-09-26, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d02de371705d, moduleTitle=常用抗血小板药物不耐受、反应性低？这些治疗策略要掌握！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d02de371705d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947228, encodeId=b865194e228d1, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=他汀不耐受怎么办？声明提出这几种替代方案, objectType=article, longId=732487, objectId=95f3e32487db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95f3e32487db, replyNumber=0, likeNumber=67, createdTime=2022-12-30, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95f3e32487db, moduleTitle=他汀不耐受怎么办？声明提出这几种替代方案, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=95f3e32487db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947227, encodeId=e0e7194e227f0, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=乳糖不耐受检测原来可以如此简单 | 检验新技术新应用, objectType=article, longId=730932, objectId=0db8e3093271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0db8e3093271, replyNumber=0, likeNumber=65, createdTime=2022-08-02, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0db8e3093271, moduleTitle=乳糖不耐受检测原来可以如此简单 | 检验新技术新应用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0db8e3093271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947229, encodeId=0da3194e2295e, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=中国真实世界经验-不耐受强化疗的老年AML患者，去甲基化药物联合低剂量化疗预后佳, objectType=article, longId=734613, objectId=49dce34613fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49dce34613fc, replyNumber=0, likeNumber=78, createdTime=2022-11-12, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49dce34613fc, moduleTitle=中国真实世界经验-不耐受强化疗的老年AML患者，去甲基化药物联合低剂量化疗预后佳, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=49dce34613fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947226, encodeId=c3ec194e2261a, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=Eur Heart J：他汀类药物不耐受的患病率, objectType=article, longId=299285, objectId=8fdf299285a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fdf299285a7, replyNumber=0, likeNumber=106, createdTime=2022-12-01, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fdf299285a7, moduleTitle=Eur Heart J：他汀类药物不耐受的患病率, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8fdf299285a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947225, encodeId=ebb4194e225f9, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=AJOG：胰岛素抵抗亚型是妊娠期葡萄糖不耐受女性不良妊娠结局的高危亚型, objectType=article, longId=216286, objectId=77ca216286da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77ca216286da, replyNumber=0, likeNumber=92, createdTime=2021-09-05, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77ca216286da, moduleTitle=AJOG：胰岛素抵抗亚型是妊娠期葡萄糖不耐受女性不良妊娠结局的高危亚型, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=77ca216286da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947223, encodeId=6fbf194e22360, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=Gut: 肠道微生物组在介导乳糖不耐受症状中的作用, objectType=article, longId=208989, objectId=f69c208989c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f69c208989c3, replyNumber=0, likeNumber=63, createdTime=2022-03-01, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f69c208989c3, moduleTitle=Gut: 肠道微生物组在介导乳糖不耐受症状中的作用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f69c208989c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947224, encodeId=3395194e22423, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=要命的！牛奶过敏和乳糖不耐受，你还傻傻分不清楚吗？, objectType=article, longId=210190, objectId=e998210190cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e998210190cb, replyNumber=0, likeNumber=63, createdTime=2021-06-28, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e998210190cb, moduleTitle=要命的！牛奶过敏和乳糖不耐受，你还傻傻分不清楚吗？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e998210190cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947222, encodeId=de78194e22289, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=美国FDA核准武田ICLUSIG® (ponatinib)用于耐药或不耐受慢性期CML成人患者的补充新药申请, objectType=article, longId=204831, objectId=316c204831cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=316c204831cf, replyNumber=0, likeNumber=73, createdTime=2021-10-03, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=316c204831cf, moduleTitle=美国FDA核准武田ICLUSIG® (ponatinib)用于耐药或不耐受慢性期CML成人患者的补充新药申请, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=316c204831cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947221, encodeId=6b31194e221d4, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=AP&T: 5-氨基水杨酸盐不耐受的溃疡性结肠炎患者接受结肠切除术的风险增加, objectType=article, longId=204677, objectId=fcec2046e76c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcec2046e76c, replyNumber=0, likeNumber=65, createdTime=2021-06-08, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcec2046e76c, moduleTitle=AP&T: 5-氨基水杨酸盐不耐受的溃疡性结肠炎患者接受结肠切除术的风险增加, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fcec2046e76c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947220, encodeId=4f8f194e22080, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=Blood：Umbralisib用于BTK或PI3Kδ抑制剂不耐受的CLL患者的疗效和耐受性, objectType=article, longId=204131, objectId=bf81204131cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf81204131cf, replyNumber=0, likeNumber=64, createdTime=2021-04-18, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf81204131cf, moduleTitle=Blood：Umbralisib用于BTK或PI3Kδ抑制剂不耐受的CLL患者的疗效和耐受性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bf81204131cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947218, encodeId=1384194e21871, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=Medicine：托西利珠单抗用于秋水仙碱无效或不耐受的家族性地中海热的疗效与安全性研究, objectType=article, longId=198094, objectId=69af1980945f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69af1980945f, replyNumber=0, likeNumber=61, createdTime=2021-04-03, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69af1980945f, moduleTitle=Medicine：托西利珠单抗用于秋水仙碱无效或不耐受的家族性地中海热的疗效与安全性研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=69af1980945f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947219, encodeId=8541194e2194c, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=阜外医院李建军等提出他汀不耐受新定义, objectType=article, longId=198780, objectId=6385198e8075, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6385198e8075, replyNumber=0, likeNumber=74, createdTime=2020-10-14, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6385198e8075, moduleTitle=阜外医院李建军等提出他汀不耐受新定义, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6385198e8075)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947216, encodeId=2efa194e216ff, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=JAHA：法洛四联症修复后右室电机械失同步vs肺动脉返流对右室功能不全和运动不耐受的影响, objectType=article, longId=158479, objectId=f2501584e95f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2501584e95f, replyNumber=0, likeNumber=52, createdTime=2019-02-24, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2501584e95f, moduleTitle=JAHA：法洛四联症修复后右室电机械失同步vs肺动脉返流对右室功能不全和运动不耐受的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f2501584e95f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947215, encodeId=16b7194e215ce, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=2019 台湾专家共识声明：他汀类药物不耐受, objectType=article, longId=157360, objectId=5a7e15e360e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a7e15e360e0, replyNumber=0, likeNumber=57, createdTime=2019-03-25, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a7e15e360e0, moduleTitle=2019 台湾专家共识声明：他汀类药物不耐受, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5a7e15e360e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947214, encodeId=6599194e214d0, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=JACC：血脂异常患者他汀不耐受营养保健品能托起治疗希望吗？, objectType=article, longId=144834, objectId=808214483470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=808214483470, replyNumber=0, likeNumber=71, createdTime=2018-07-27, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=808214483470, moduleTitle=JACC：血脂异常患者他汀不耐受营养保健品能托起治疗希望吗？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=808214483470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947217, encodeId=c0c8194e217ad, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=Curr HIV Res：药物不耐受转换为Eviplera®药物治疗后患者的表现, objectType=article, longId=162394, objectId=2e1b162394a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e1b162394a7, replyNumber=0, likeNumber=47, createdTime=2020-02-03, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e1b162394a7, moduleTitle=Curr HIV Res：药物不耐受转换为Eviplera®药物治疗后患者的表现, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2e1b162394a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947212, encodeId=9d55194e21220, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=Intern Med J:电子病历中青霉素ADR记录：过敏和不耐受傻傻分不清, objectType=article, longId=121707, objectId=1b7a121e07d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b7a121e07d0, replyNumber=0, likeNumber=73, createdTime=2018-05-20, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b7a121e07d0, moduleTitle=Intern Med J:电子病历中青霉素ADR记录：过敏和不耐受傻傻分不清, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1b7a121e07d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947209, encodeId=0678194e20909, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=JACC：他汀不耐受与心梗复发和冠心病风险增加相关？, objectType=article, longId=98250, objectId=b5c7982501d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5c7982501d, replyNumber=0, likeNumber=53, createdTime=2017-11-25, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5c7982501d, moduleTitle=JACC：他汀不耐受与心梗复发和冠心病风险增加相关？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b5c7982501d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947213, encodeId=3bd6194e213bb, content=<a href='/topic/show?id=78af204639e' target=_blank style='color:#2F92EE;'>#不耐受#</a>, objectTitle=J Occup Environ Med：化学和建筑相关不耐受气道炎症性疾病的并发症分析, objectType=article, longId=125104, objectId=7f21125104b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f21125104b7, replyNumber=0, likeNumber=62, createdTime=2018-02-13, rootId=0, userName=ms8543593053280928, userId=023c2500122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f21125104b7, moduleTitle=J Occup Environ Med：化学和建筑相关不耐受气道炎症性疾病的并发症分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7f21125104b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

不耐受

2020-05-29

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

常用抗血小板药物不耐受、反应性低？这些治疗策略要掌握！

2022-09-26

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

他汀不耐受怎么办？声明提出这几种替代方案

2022-12-30

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

乳糖不耐受检测原来可以如此简单 | 检验新技术新应用

2022-08-02

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

中国真实世界经验-不耐受强化疗的老年AML患者，去甲基化药物联合低剂量化疗预后佳

2022-11-12

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

Eur Heart J：他汀类药物不耐受的患病率

2022-12-01

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

AJOG：胰岛素抵抗亚型是妊娠期葡萄糖不耐受女性不良妊娠结局的高危亚型

2021-09-05

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

Gut: 肠道微生物组在介导乳糖不耐受症状中的作用

2022-03-01

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

要命的！牛奶过敏和乳糖不耐受，你还傻傻分不清楚吗？

2021-06-28

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

美国FDA核准武田ICLUSIG® (ponatinib)用于耐药或不耐受慢性期CML成人患者的补充新药申请

2021-10-03

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

AP&T: 5-氨基水杨酸盐不耐受的溃疡性结肠炎患者接受结肠切除术的风险增加

2021-06-08

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

Blood：Umbralisib用于BTK或PI3Kδ抑制剂不耐受的CLL患者的疗效和耐受性

2021-04-18

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

Medicine：托西利珠单抗用于秋水仙碱无效或不耐受的家族性地中海热的疗效与安全性研究

2021-04-03

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

阜外医院李建军等提出他汀不耐受新定义

2020-10-14

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

JAHA：法洛四联症修复后右室电机械失同步vs肺动脉返流对右室功能不全和运动不耐受的影响

2019-02-24

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

2019 台湾专家共识声明：他汀类药物不耐受

2019-03-25

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

JACC：血脂异常患者他汀不耐受营养保健品能托起治疗希望吗？

2018-07-27

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

Curr HIV Res：药物不耐受转换为Eviplera®药物治疗后患者的表现

2020-02-03

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

Intern Med J:电子病历中青霉素ADR记录：过敏和不耐受傻傻分不清

2018-05-20

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

JACC：他汀不耐受与心梗复发和冠心病风险增加相关？

2017-11-25

ms8543593053280928 (审核中...)

前往app查看评论内容

#不耐受#

J Occup Environ Med：化学和建筑相关不耐受气道炎症性疾病的并发症分析

2018-02-13

科室
- - 订阅+
  - 更多科室
工具
服务